An additional study on PLX51107 investigated its use in MYC-driven lymphomas, namely, DLBCL, and found that PLX51107 drove both MYC downregulation in DLBCL cells and BIM-dependent apoptosis that promotes synergy with venetoclax (Bcl-2 inhibitor).280 Success of PLX51107 in preclinical studies have pushed it into a phase I clinical trial that is currently ongoing to evaluate safety, PK, pharmacodynamics, and clinical activity in combination with azacitidine AML and MDS patients. This evidence concerns the gene BCL2 and acute myeloid leukemia.